SCHEMBL560422

SCHEMBL560422

CC(C)(C)NC(CS)C(=O)O

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.54
KDM4E B2RXH2 1/20 0.54
THRB P10828 1/20 0.54
ALOX15 P16050 1/20 0.54
NFKB1 P19838 1/20 0.54
PTGS2 P35354 1/20 0.54
THPO P40225 1/20 0.54
RECQL P46063 1/20 0.54
BLM P54132 1/20 0.54
SMN1; SMN2 Q16637 1/20 0.54
ACE P12821 2/20 0.48
FOLH1 Q04609 3/20 0.41
PTGS1 P23219 2/20 0.36
SLC7A11 Q9UPY5 1/20 0.36
CPB2 Q96IY4 2/20 0.35
NAALAD2 Q9Y3Q0 2/20 0.33
ALDH1A1 P00352 2/20 0.33
CA1 P00915 1/20 0.33
CA2 P00918 1/20 0.33
ENPEP Q07075 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3923217 1.00 MAPT (0.54) MAPTKDM4ETHRBALOX15NFKB1
SCHEMBL560423 1.00 MAPT (0.54) MAPTKDM4ETHRBALOX15NFKB1
SCHEMBL1396850 0.83 MAPT (0.50) MAPTKDM4ETHRBALOX15NFKB1
SCHEMBL25962782 0.82 KDM4E (0.43) MAPTKDM4ETHRBALOX15NFKB1
SCHEMBL30612980 0.81 ACE (0.48) MAPTKDM4ETHRBALOX15NFKB1
SCHEMBL27400867 0.80 SMN1; SMN2 (0.38) MAPTKDM4ETHRBALOX15NFKB1
SCHEMBL15745110 0.80 KDM4E (0.38) MAPTKDM4ETHRBALOX15NFKB1
SCHEMBL10540962 0.80 SMN1; SMN2 (0.38) MAPTKDM4ETHRBALOX15NFKB1
SCHEMBL19229970 0.80 KDM4E (0.38) MAPTKDM4ETHRBALOX15NFKB1
SCHEMBL24513378 0.79 KDM4E (0.47) MAPTKDM4ETHRBALOX15NFKB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260001922-A1 PEPTIDES TARGETING SODIUM CHANNELS TO TREAT PAIN UNIV CALIFORNIA (US) 2026-01-01 US claimed
CN-118239879-A Method for preparing 3-substituted oxindole, dihydroisoindigo and tetra-substituted ethane based on primary amine and application of primary amine 泰山学院 2024-06-25 CN claimed
WO-2024011119-A2 PEPTIDES TARGETING SODIUM CHANNELS TO TREAT PAIN THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2024-01-11 WO claimed
EP-3365354-B1 PEPTIDES AND PEPTIDOMIMETICS IN COMBINATION WITH T CELL ACTIVATING AND/OR CHECKPOINT INHIBITING AGENTS FOR CANCER TREATMENT CANBAS CO LTD (JP) 2026-02-11 EP disclosed
US-20260001922-A1 PEPTIDES TARGETING SODIUM CHANNELS TO TREAT PAIN UNIV CALIFORNIA (US) 2026-01-01 US disclosed
CN-118239879-A Method for preparing 3-substituted oxindole, dihydroisoindigo and tetra-substituted ethane based on primary amine and application of primary amine 泰山学院 2024-06-25 CN disclosed
WO-2024011119-A2 PEPTIDES TARGETING SODIUM CHANNELS TO TREAT PAIN THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2024-01-11 WO disclosed
US-11560359-B2 Oxopiperazine helix mimetics for control of hypoxia-inducible gene expression NEW YORK UNIVERSITY (US) 2023-01-24 US disclosed
US-20220183291-A1 COMPOSITIONS AND METHODS FOR MODULATING IMMUNITY IN PLANTS BOYCE THOMPSON INSTITUTE FOR PLANT RESEARCH, INC. 2022-06-16 US disclosed
US-20210171473-A1 OXOPIPERAZINE HELIX MIMETICS FOR CONTROL OF HYPOXIA-INDUCIBLE GENE EXPRESSION UNIV NEW YORK (US) 2021-06-10 US disclosed
CN-112638366-A Metabolizable pH-sensitive polymersome UCL商业有限公司 2021-04-09 CN disclosed
EP-1109827-A2 BIOACTIVE PEPTIDES ALPHARMA AS (NO) 2001-06-27 EP disclosed
WO-2000012542-A2 CYTOTOXIC LACTOFERRIN DERIVATIVES MODIFIED BY BULKY OR LIPOPHILIC MOIETIES ALPHARMA AS (NO) 2000-03-09 WO disclosed
US-5612036-A CROSSLINKED POLYPEPTIDE VACCINE WITH CYSTEINE GROUPS AND CARRIERS THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) 1997-03-18 US disclosed
US-5445818-A Immunization using active cyclic polypeptide having cysteine groups crosslinked THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) 1995-08-29 US disclosed
EP-0469045-B1 SYNTHETIC $i(PSEUDOMONAS) $i(AERUGINOSA) PILIN PEPTIDE AND RELATED VACCINES AND DIAGNOSTICS UNIV ALBERTA (CA) 1994-06-15 EP disclosed
EP-0546063-A1 TOXIC AGENT PROTECTIVE COMPOUNDS, COMPOSITIONS AND USES The Secretary of State for Defence in Her Britannic Majesty's Government of the United Kingdom of Great Britain and (GB) 1993-06-16 EP disclosed
WO-1992004024-A2 TOXIC AGENT PROTECTIVE COMPOUNDS, COMPOSITIONS AND METHOD THE SECRETARY OF STATE FOR DEFENCE IN HER BRITANNIC MAJESTY'S GOVERNMENT OF THE UNITED KINGDOM OF GREAT BRITAIN AND NORTHERN IRELAND (GB) 1992-03-19 WO disclosed
EP-0469045-A1 SYNTHETIC -i(PSEUDOMONAS) -i(AERUGINOSA) PILIN PEPTIDE AND RELATED VACCINES AND DIAGNOSTICS. UNIV ALBERTA (CA) 1992-02-05 EP disclosed
WO-1990013563-A1 SYNTHETIC PSEUDOMONAS AERUGINOSA PILIN PEPTIDE AND RELATED VACCINES AND DIAGNOSTICS THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) 1990-11-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210171473-A1 OXOPIPERAZINE HELIX MIMETICS FOR CONTROL OF HYPOXIA-INDUCIBLE GENE EXPRESSION CREBBP, CREB1, EP300 MAPT 4551/4885KDM4E 1240/4885THRB 210/4885
US-20220183291-A1 COMPOSITIONS AND METHODS FOR MODULATING IMMUNITY IN PLANTS IFNG, STING1, IRF3 MAPT 3890/4885KDM4E 3904/4885THRB 4448/4885
US-20260001922-A1 PEPTIDES TARGETING SODIUM CHANNELS TO TREAT PAIN TPX2, XBP1, SCN9A MAPT 3814/4885KDM4E 1772/4885THRB 1416/4885
US-11560359-B2 Oxopiperazine helix mimetics for control of hypoxia-inducible gene expression CREBBP, CREB1, EP300 MAPT 4551/4885KDM4E 1240/4885THRB 210/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.